Analysts are setting expectations for Pfizer's second-quarter earnings, with investors keenly awaiting the pharmaceutical giant's financial report.

Pfizer announced that its Chief Financial Officer, Dave Denton, will step down from his position effective August 15.

Bank of America has increased its price target for Pfizer after the pharmaceutical giant reported strong first-quarter earnings.

Pfizer (PFE) is highlighted as one of the best high-volume stocks for investment, according to recent analysis.

Financial analysts are presenting varied perspectives on Pfizer (PFE) stock, with some expressing bullish sentiment and recommending it as a strong investment. Others, like Morgan Stanley, maintain an "Equal Weight" rating due to patent concerns, while still considering it among the best medical stocks.

Bank of America has raised its price target for Teva Pharmaceutical (TEVA) stock to $42.

Guggenheim analysts have identified a favorable risk-reward scenario for Pfizer's stock (PFE) as the company approaches the release of its Phase 3 clinical trial data.

An investor shares a reason why they would happily buy Pfizer (PFE) stock and never sell, offering a long-term bullish perspective.

Pfizer (PFE) has announced that the FDA has approved PADCEV in combination with Keytruda for the treatment of MIBC (muscle-invasive bladder cancer).

An investment analysis suggests Pfizer (PFE) is a leading longevity stock to consider buying now, highlighting its potential in the growing market for health and aging-related investments.

A Wall Street analyst has projected a potential 38% increase in Pfizer (PFE) stock, suggesting a strong outlook for the pharmaceutical company.

Guggenheim analysts have reiterated their 'Buy' rating for Pfizer, anticipating positive catalysts from the pharmaceutical giant's upcoming pipeline developments.

Pfizer (PFE) is being evaluated as one of the best Fortune 500 dividend stocks for investment, suggesting its strong position for dividend-seeking investors.

Investors are reportedly bearish on Pfizer (PFE) as its substantial dividend fails to mask underlying concerns about the company's growth prospects.

RBC Capital initiates coverage on Pfizer (PFE) with a $25 target, highlighting structural revenue headwinds.

Pfizer (PFE) has reaffirmed its fiscal year 2026 outlook despite recent leadership changes. The company maintains its financial projections for the coming years.

Analysts have released conflicting sentiments on several consumer cyclical companies, including Citi Trends, Caesars Entertainment, and Yeti Holdings. Additionally, insights were provided for healthcare companies like Phreesia, Agilent, and Pfizer, and other consumer cyclical firms such as Tesla and BMW.

Wolfe Research reports that ongoing uncertainty surrounding COVID-19 continues to negatively impact the financial outlook for pharmaceutical giant Pfizer (PFE).

UBS has revised its outlook for the pharmaceutical sector and increased its price target for Pfizer (PFE).

Pfizer (PFE) has been highlighted as one of the top 15 large-cap stocks offering the highest dividends.

Argus adopts a bullish stance on Pfizer, emphasizing the company's GLP-1 and oncology pipeline developments.